Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study

Carlos Roncero, Carmen Barral, Laia Rodríguez-Cintas, Jesús Pérez-Pazos, Nieves Martinez-Luna, Miguel Casas, Marta Torrens, Lara Grau-López

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)

Abstract

© 2016 Elsevier Ireland Ltd Opioid-dependent patients show a high rate of psychiatric comorbidities. The prevalence and characteristics of patients with dual diagnosis have not been well established in Spanish opioid agonist treatment (OAT) programmes. Thus, 621 opioid-dependent patients enrolled in OAT programmes were assessed, using the EuropASI questionnaire, for psychiatric comorbidities, which were detected in 67% of patients (anxiety 53%, mood disorders 48%, sleep disorders 41%, substance-related disorders 36%). In addition, compared with patients without a dual diagnosis, patients with dual pathology were significantly older, used benzodiazepines and cannabis in significantly greater percentages, and showed significantly more frequent infectious and non-infectious comorbidities, worse overall working status, a lower proportion of drivers and higher levels of severity regarding medical, employment, alcohol, legal, family and psychological issues. Therefore, the data showed a very high prevalence of psychiatric comorbidity in opioid-dependent patients receiving OAT in Spain and several problems frequently associated with patients with dual diagnosis. Physicians treating opioid-dependent patients should be aware of these facts to correctly identify and manage patients with a dual diagnosis.
Original languageEnglish
Pages (from-to)174-181
JournalPsychiatry Research
Volume243
DOIs
Publication statusPublished - 30 Sep 2016

Keywords

  • Comorbidity
  • Dual diagnosis
  • EuropASI questionnaire
  • Methadone
  • Opioid agonist treatment
  • Opioid dependence
  • Psychiatric

Fingerprint Dive into the research topics of 'Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study'. Together they form a unique fingerprint.

Cite this